KN5501 cell therapy for refractory lupus
Part of Immune system & allergy clinical trials.
This trial tests a new treatment called KN5501 (a type of cell therapy) for people with lupus that hasn't been controlled by usual medicines. It aims to see if this treatment can help calm the immune system and reduce lupus activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old
- You have lupus that is not responding to standard treatments and is moderate to severe
- Your blood counts (white cells, red cells, platelets) are at certain levels
- Your liver, kidneys, lungs, and heart are working well enough
- You do not have severe lupus affecting your kidneys or brain
- You do not have active serious infections like TB, hepatitis B/C, or HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment for adults with systemic lupus erythematosus (SLE) that hasn't improved with standard therapies. It aims to see if targeting CD19 cells can calm the disease.
This trial tests a new cell therapy (RY_SW01) for people with active lupus nephritis (kidney inflammation caused by lupus) who haven't responded well to standard treatments. It aims to see if the therapy can help control the disease.
This trial tests a new CAR-T cell therapy for people with severe lupus that hasn't improved with standard treatments. The therapy uses specially designed immune cells to target and destroy cells causing the disease.
This trial tests a new immune cell therapy (CAR NK cells) for people with moderate to severe lupus that hasn't responded well to standard treatments. The therapy targets a protein called CD19 on certain immune cells to calm the overactive immune system.
This trial tests a new treatment called CRC01, made from your own cells, for people with severe lupus that hasn't improved with standard medications. The goal is to see if it can safely control the disease and reduce symptoms.
This trial tests whether a personalized cell therapy called CD19 CAR-T can help people with hard-to-treat lupus (SLE). The treatment uses your own immune cells that have been modified to attack faulty B cells, which are involved in lupus. It is for patients who have moderate to severe disease despite trying multiple standard treatments.
Hear when a new Systemic Lupus Erthematosus (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.